explore -WSS

explore

author：entertainment 2025-09-27 10:02:36 - browse：9

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： CEOs share strategies for surviving biotech slump

explore

WSS

First Opinion Podcast: Long Covid needs a new approach

UnitedHealth’s board chair also owns a personal investment firm

Who is Jack Smith, the special counsel overseeing the DOJ's Trump probes?

Medicare reduced heart disease by changing how it pays doctors

STAT Summit: GSK CEO on pharma giant's new direction

HHS leader on health, climate change and biopharma emissions

hotspot

explore

hotspot

Medical records are filled with copy

Eli Lilly expects to double planned employment in Boston center

Medicare proposal to cover medical devices draws a mixed reaction

Medicare reduced heart disease by changing how it pays doctors

Cancer drug shortages should be causing more outrage

Senate committee scrutinizes Medicare Advantage brokers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Eli Lilly expects to double planned employment in Boston center

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Lawmakers consider Medicare pay reforms for doctors

explore

FDA warns J&J's Abiomed: We will regulate your software

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

2023 STAT Wunderkinds: get to know the winners

A controversial new treatment promises to make little people taller

Alnylam reports growth in sales of rare disease treatments

Will Ozempic

explore

explore

explore

leisure time